Scandinavian ChemoTech obtains two patent approvals for the key features of the technical platform Tumour Specific Electroporation
Scandinavian ChemoTech (ChemoTech) has today announced that the company has received the final notice from the Swedish patent Authorities (PRV) for two of its patent applications. These new patents will create a fundamental protection of the unique technology platform that the company has innovated which is the backbone both for the device IQwave as well as the company’s R&D portfolio.ChemoTech is a Swedish medtech company that has developed a technology platform to offer cancer patients who cannot be treated with conventional methods access to a new treatment alternative, Dynamic-